A Mechanistic Study to Assess a Single Dose of CYB003 in Participants With Depression and Anxiety (NCT06820723)
A Randomized, Double-Blind, Placebo-Controlled Mechanistic Study to Assess a Single Oral Dose of CYB003 in Participants With Major Depressive Disorder (MDD) and Moderate to Severe Anxiety
🩺 Plain-English Summary (8th-Grade Level)
The goal of this study is to learn how psychedelics may help symptoms of depression and anxiety. Participants with major depressive disorder experiencing symptoms of depression and anxiety will receive one dose of either a drug related to psilocybin or a placebo. Assessments include interviews, self-report questionnaires, EEG and fMRI to measure symptoms and brain function.
Who can join: Review the eligibility criteria below.
Location: The Ohio State University Department of Psychiatry — Columbus, Ohio
Age range: 21 Years to 65 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- The Ohio State University Department of Psychiatry — Columbus, Ohio
📞 Contact the Study Coordinator
Phone: (614) 293-5517
Email: anne-marie.duchemin@osumc.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Depression
- Neural Circuit Biomarkers of Transcranial Magnetic Stimulation Study — Stanford, California
- Meditation Accelerated Brain Stimulation for Depression — San Diego, California
- A Behavioral Activation Prenatal and Postpartum Intervention for Depressed Pregnant Smokers — Houston, Texas
- EEG Biomarker Study for Participants in the Neurolief "MOOD" Trial — Providence, Rhode Island
- Using rTMS to Treat Depression — Miami, Florida
- Integrating Ketamine Effects on Neuronal Molecular Signatures and the Brain Functional and Structural Connectome — Boston, Massachusetts
Explore by condition: All Depression clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.